Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacol Res. 2007 Nov;56(5):360-6. Epub 2007 Sep 11.

Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Author information

1
Department of Pharmacology and Center for Drug Discovery, The University of California, Irvine, CA 92697, USA.

Abstract

Cannabinoids are well known modulators of mood and emotional behavior. Current research supports a role for endocannabinoid signaling in the treatment of depression. Changes in levels of the cannabinoid CB(1) receptor or the endogenous CB(1) receptor ligands, anandamide and 2-AG, are observed both in humans suffering from depression and in animal models of depression, and experimental manipulation of CB(1) receptor signaling has also been shown to affect emotional reactivity in rodents. Importantly, inhibitors of anandamide inactivation have demonstrated efficacy in enhancing stress-coping and mood-related behavior. This article will review these areas of research, highlighting the potential of endocannabinoid metabolism modulators as therapeutics for the treatment of depression.

PMID:
17945507
PMCID:
PMC2104793
DOI:
10.1016/j.phrs.2007.09.003
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center